Relevant influencing factors and application status of MammaPrint in early-stage breast cancer:A muti-center observational study

XU Jialu; GU Minghao; ZHUANG Minyu; ZHU Yanhui; WU Xian; YU Xiafei; YANG Junzhe; QIAN Fangze; ZHANG Ziwei; CHENG Xuyu; LIU Xiao'an

doi:10.3969/j.issn.1674-4136.2024.03.004

Abstract：Objective The genomic test is a significant instrument for the prognostic assessment of breast cancer.This study investigated the current application status of the MammaPrint in early-stage breast cancer in 28 tertiary hospitals in Jiangsu Province,to explore its relevant influencing factors,and to examine its impact on the selection of adjuvant treatment strategies.Methods A cross-sectional approach was used to collect clinical information and pathological data from female breast cancer patients who underwent MammaPrint at multiple centers from May 2019 to March 2023.Their clinical risk and genomic risk were determined,and treatment strategies were documented.Results Histological grade and Ki67(P＜0.01)were significantly different in distinct gene risk groups,whereas there were no significant differences in these groups for such variables as age and lymph node status.Further including these variables in logistic regression analysis,G3 as well as Ki67≥10％were confirmed to be the main risk factors for high genomic risk(P＜0.05).Regarding treatment approaches,89.5％of patients were able to adhere to the recommendations from the MINDACT trial,and 10.9％of low-clinical-risk individuals had changes in their treatment plans.In addition,it's necessary to note that by integrating MammaPrint with BluePrint,individual cases of Basal-type and HER2-type breast cancer were identified within the high genomic risk group.Conclusions Currently,adjuvant treatment decisions for early-stage breast cancer patients in China tend to be conservative.However,MammaPrint scores exhibit significant differences in distinct histological grades and Ki67 status.Therefore,MammaPrint could be considered to direct the de-escalation or escalation of therapies for particular patient groups.